Key Insights: 22nd Annual Perspectives in Thoracic Oncology

Key Insights: 22nd Annual Perspectives in Thoracic Oncology

On-Demand Webcast

Corey J. Langer, MD, FACP
University of Pennsylvania
Philadelphia, Pennsylvania


Joshua Bauml, MD
University of Pennsylvania
Philadelphia, Pennsylvania

Target Audience

This educational activity is designed for community-based medical oncologists and other healthcare professionals (oncology nurses, pharmacists, physician assistants, etc.) in the United States who are involved and/or interested in the treatment of patients with lung cancer.


Recent advances continue to evolve our knowledge base and care strategies for lung cancer. The 22nd Annual Perspectives in Thoracic Oncology, held in New York City from November 17-18, 2017, was an unparalleled educational educational event featuring US-based experts in lung cancer and engaged attendees. This activity features conference chair Corey J. Langer, MD and guest faculty Joshua Bauml, MD discussing the key take-home points from this year’s conference.


Upon successful completion of this educational activity, participants should be better able to:

  1. Determine the clinical relevance of emerging data from trials evaluating targeted therapies and immunotherapy for NSCLC
  2. Evaluate progress being made in targeting less common markers, such as HER2, BRAF, KRAS, MET, TRK, and RET in lung cancer management
  3. Develop a strategy for individualized management of patients with lung cancer

This activity is provided by Imedex®, LLC.

Continuing Education


Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this internet-based enduring educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.5 hour of Category 1 credit for completing this program.

In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.


Supported by educational grants from: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc., and Novartis Pharmaceuticals Corporation


As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are instructed to provide a balanced view of therapeutic options by utilizing generic names to ensure impartiality.

All faculty participating in an Imedex activity are required to disclose relevant financial relationships that may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.

1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support

Joshua Bauml, MD AstraZeneca Pharmaceuticals LP2; Bayer HealthCare Pharmaceuticals1; Boehringer Ingelheim Pharmaceuticals, Inc.2; Bristol-Myers Squibb2; Carevive Systems1; Celgene2; Clovis2; Guardant Health2; Genetech2; Merck1,2; Novartis Pharmaceuticals Corporation1
Corey J. Langer, MD, FACP Abbott Labratories2; Advantagene1; Amgen5; Ariad Pharmaceuticals, Inc.1,2; AstraZeneca Pharmaceuticals LP2; Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Inc.2; Biodesix2; Boehringer Ingelheim Pharmaceuticals, Inc.2; Bristol-Myers Squibb Company2; CarisDx2; CCO3; Celgene1,2; Clariant2; Clovis1,2; Eli Lilly and Company1,2,5; Genetech, Inc.2; GlaxoSmithKline1; ImClone Systems Incorporated2; Incyte5; Inovio1; Merck1; MLG3; Nektar1; NOCR3; Novartis Pharmaceuticals Corporation2; PER3; Peregrine5; Pfizer Inc1,2; PIK3; RTP3; Synta Pharmaceuticals Corp2,5; SWOG5

All materials are included with the permission of the authors.

Imedex, LLC Staff Disclosure of Financial Relationships
All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following individuals:

   Chris Bolwell owns shares of stock of GlaxoSmithKline.

Unapproved Uses

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.

The opinions expressed in this webcast are the opinions of the authors and do not necessarily reflect the opinions of Imedex.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

About Imedex

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

© 2018 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

For comments or inquiries, please contact:
Imedex, LLC
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Fax: +1(770) 751-7334

Release Date: December 29, 2017

Expiration Date: December 29, 2018